Former Wisconsin Rep. Mike Gallagher joined 'America's Newsroom' to discuss Trump's tariff threat against China and his ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

One of the Charlotte region's top economic development players has been hired by a pharmaceutical giant establishing a ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...